RecruitingPhase 3NCT04499755
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics: A Randomized Controlled Trial
Sponsor
Sherief Abd-Elsalam
Enrollment
100 participants
Start Date
Jun 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Eligibility
Max Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Nucleo CMP Forte for people with brain injuries. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 18 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNucleo CMP Forte
Nucleo CMP Forte twice daily for 6 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04499755
Related Trials
The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and Neurologic Symptoms
NCT066075231 location
Biomarker Role in Assessing Imaging Needs for Mild Cranial Trauma
NCT069325881 location
The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients
NCT0500892611 locations
Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
NCT064131732 locations
Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions
NCT025922911 location